Two peptides share the name “Thymosin” but have fundamentally different biology. Thymosin Alpha-1 is an immunomodulatory peptide with TLR signaling activity; TB-500 is a fragment of Thymosin Beta-4 that regulates actin dynamics and tissue repair in preclinical models. A fact-based research comparison.
Medically reviewed by Dr. Sieglinde Klaus · Last reviewed June 2026
Thymosin Alpha-1 (Talpha1) and TB-500 (Thymosin Beta-4 fragment) share only the name “Thymosin” but belong to different, unrelated peptide families.
Neither is approved for the research purposes described here. TB-500/Thymosin Beta-4 has been prohibited at all times by WADA (Section S2) since 2011. The choice depends entirely on the research endpoint: immunological questions favor Talpha1, tissue-related regeneration models favor TB-500.
Immunomodulator: TLR2/TLR9 signaling via MyD88, maturation of dendritic cells, Th1 polarization, IFN-gamma/IL-2 stimulation
Actin sequestration via the LKKTETQ motif; regulates polymerization/depolymerization, cell migration, angiogenesis
Immune restoration: chronic hepatitis B, adjunctive oncology research, immunodeficiency models
Tissue repair: wound healing, cardiac repair, angiogenesis, tendon/muscle injury (predominantly preclinical)
1.6 mg (approx. 900 µg/m2) subcutaneously twice weekly, 6-12 months (clinical regimen)
Thymosin Alpha-1 is a pleiotropic immunomodulator that acts primarily at the interface between innate and adaptive immunity. Its main molecular targets are:
Talpha1 is not a tissue repair or angiogenesis peptide. N-terminal acetylation is structurally important for full biological activity and improves stability against aminopeptidases 1.
comprises the central active region of , a naturally occurring 43-amino-acid polypeptide (approx. 4.96 kDa) and the most abundant intracellular G-actin-binding protein in mammalian tissue. The core mechanism is:
Thymosin Alpha-1 (as thymalfasin) is considered very well tolerated across more than 2,000 treated patients; adverse events are rare and predominantly mild. The short half-life and lack of accumulation contribute to the favorable tolerability profile. All applications described here are discussed exclusively in a research context.
Thymosin Beta-4 was generally safe and well tolerated in completed human studies (IV up to 1260 mg, topical, ophthalmic), without dose-limiting toxicity or treatment-related serious adverse events. For the TB-500 fragment itself, however, dedicated human data are lacking, and the pro-angiogenic properties raise unquantified long-term questions.
Thymosin Alpha-1 is the only one of the two peptides with documented activity on TLR2/TLR9 and dendritic cells [3]. For questions about Th1 polarization, IFN-gamma/IL-2 stimulation, or immune restoration, TB-500 is mechanistically irrelevant, since it addresses the cytoskeleton and not immune receptors.
TB-500 (Thymosin Beta-4 fragment) has been studied in preclinical models for effects on cell migration, endothelial tubule formation, and wound-healing processes via actin dynamics [6]. For wound healing, angiogenesis, or cardiac repair models, it provides the appropriate mechanistic basis; Talpha1 has no established role here.
TB-500/Tbeta4 has been prohibited at all times by WADA (Section S2) since 2011. Where a sports context or anti-doping compliance is relevant, TB-500 is generally unsuitable. Thymosin Alpha-1 is not subject to this general prohibition and is the less problematic choice in this context.
Thymosin Alpha-1 exists as an approved drug product with a clearly defined regimen (1.6 mg s.c. twice weekly) and a safety dossier covering more than 2,000 patients [4]. For the TB-500 fragment, a validated human dose is entirely lacking, which complicates reproducible study protocols.
No. Despite the shared name, they belong to different, unrelated peptide families. Thymosin Alpha-1 is a 28-amino-acid immunomodulator that acts via TLR2/TLR9 and dendritic cells 3. TB-500 comprises the active region of Thymosin Beta-4, a 43-amino-acid actin-binding peptide that regulates cell migration and tissue repair. They differ completely in sequence, size, target, and function.
Thymosin Alpha-1 has the more solid clinical evidence base: it is available as an approved drug product (thymalfasin/Zadaxin), with data on more than 2,000 patients 4. Thymosin Beta-4 reached Phase 3 only in a narrow ophthalmic indication; the actual TB-500 fragment has virtually no human data of its own, and the evidence for it rests on full-length Tbeta4 studies plus preclinical rodent models 7.
TB-500/Thymosin Beta-4 has been prohibited at all times since 2011 under Section S2 of the WADA Prohibited List (peptide hormones, growth factors, and related substances). For researchers working in a sports context or anti-doping compliance, this is a crucial difference. Thymosin Alpha-1 is not subject to this general prohibition.
No blanket winner can be named, because Thymosin Alpha-1 and TB-500 address fundamentally different biological problems.
Where data maturity, an established dosing regimen, and anti-doping compliance are decisive, Thymosin Alpha-1 has the advantage. Where the research endpoint specifically involves actin dynamics and tissue regeneration, Talpha1 cannot replace TB-500. The decision follows the mechanism, not any general superiority.
The two peptides have orthogonal mechanisms (immune receptor agonism via TLR2/TLR9 vs. G-actin sequestration) and non-overlapping research endpoints. A winner exists only within a specific context: Thymosin Alpha-1 for immunology research, clinical data maturity, and anti-doping compliance; TB-500 for tissue repair and angiogenesis models. Since the evidence bases are asymmetric and not directly comparable and no head-to-head studies exist, a context-dependent verdict (no single overall winner) is the only factually correct one.
Two peptides share the name “Thymosin” but have fundamentally different biology. Thymosin Alpha-1 is an immunomodulatory peptide with TLR signaling activity; TB-500 is a fragment of Thymosin Beta-4 that regulates actin dynamics and tissue repair in preclinical models. A fact-based research comparison.
Medically reviewed by Dr. Sieglinde Klaus · Last reviewed June 2026Thymosin Alpha-1 (Talpha1) and TB-500 (Thymosin Beta-4 fragment) share only the name “Thymosin” but belong to different, unrelated peptide families.
Neither is approved for the research purposes described here. TB-500/Thymosin Beta-4 has been prohibited at all times by WADA (Section S2) since 2011. The choice depends entirely on the research endpoint: immunological questions favor Talpha1, tissue-related regeneration models favor TB-500.
Immunomodulator: TLR2/TLR9 signaling via MyD88, maturation of dendritic cells, Th1 polarization, IFN-gamma/IL-2 stimulation
Actin sequestration via the LKKTETQ motif; regulates polymerization/depolymerization, cell migration, angiogenesis
Immune restoration: chronic hepatitis B, adjunctive oncology research, immunodeficiency models
Tissue repair: wound healing, cardiac repair, angiogenesis, tendon/muscle injury (predominantly preclinical)
1.6 mg (approx. 900 µg/m2) subcutaneously twice weekly, 6-12 months (clinical regimen)
Thymosin Alpha-1 is a pleiotropic immunomodulator that acts primarily at the interface between innate and adaptive immunity. Its main molecular targets are:
Talpha1 is not a tissue repair or angiogenesis peptide. N-terminal acetylation is structurally important for full biological activity and improves stability against aminopeptidases 1.
comprises the central active region of , a naturally occurring 43-amino-acid polypeptide (approx. 4.96 kDa) and the most abundant intracellular G-actin-binding protein in mammalian tissue. The core mechanism is:
Thymosin Alpha-1 (as thymalfasin) is considered very well tolerated across more than 2,000 treated patients; adverse events are rare and predominantly mild. The short half-life and lack of accumulation contribute to the favorable tolerability profile. All applications described here are discussed exclusively in a research context.
Thymosin Beta-4 was generally safe and well tolerated in completed human studies (IV up to 1260 mg, topical, ophthalmic), without dose-limiting toxicity or treatment-related serious adverse events. For the TB-500 fragment itself, however, dedicated human data are lacking, and the pro-angiogenic properties raise unquantified long-term questions.
Thymosin Alpha-1 is the only one of the two peptides with documented activity on TLR2/TLR9 and dendritic cells [3]. For questions about Th1 polarization, IFN-gamma/IL-2 stimulation, or immune restoration, TB-500 is mechanistically irrelevant, since it addresses the cytoskeleton and not immune receptors.
TB-500 (Thymosin Beta-4 fragment) has been studied in preclinical models for effects on cell migration, endothelial tubule formation, and wound-healing processes via actin dynamics [6]. For wound healing, angiogenesis, or cardiac repair models, it provides the appropriate mechanistic basis; Talpha1 has no established role here.
TB-500/Tbeta4 has been prohibited at all times by WADA (Section S2) since 2011. Where a sports context or anti-doping compliance is relevant, TB-500 is generally unsuitable. Thymosin Alpha-1 is not subject to this general prohibition and is the less problematic choice in this context.
Thymosin Alpha-1 exists as an approved drug product with a clearly defined regimen (1.6 mg s.c. twice weekly) and a safety dossier covering more than 2,000 patients [4]. For the TB-500 fragment, a validated human dose is entirely lacking, which complicates reproducible study protocols.
No. Despite the shared name, they belong to different, unrelated peptide families. Thymosin Alpha-1 is a 28-amino-acid immunomodulator that acts via TLR2/TLR9 and dendritic cells 3. TB-500 comprises the active region of Thymosin Beta-4, a 43-amino-acid actin-binding peptide that regulates cell migration and tissue repair. They differ completely in sequence, size, target, and function.
Thymosin Alpha-1 has the more solid clinical evidence base: it is available as an approved drug product (thymalfasin/Zadaxin), with data on more than 2,000 patients 4. Thymosin Beta-4 reached Phase 3 only in a narrow ophthalmic indication; the actual TB-500 fragment has virtually no human data of its own, and the evidence for it rests on full-length Tbeta4 studies plus preclinical rodent models 7.
TB-500/Thymosin Beta-4 has been prohibited at all times since 2011 under Section S2 of the WADA Prohibited List (peptide hormones, growth factors, and related substances). For researchers working in a sports context or anti-doping compliance, this is a crucial difference. Thymosin Alpha-1 is not subject to this general prohibition.
No blanket winner can be named, because Thymosin Alpha-1 and TB-500 address fundamentally different biological problems.
Where data maturity, an established dosing regimen, and anti-doping compliance are decisive, Thymosin Alpha-1 has the advantage. Where the research endpoint specifically involves actin dynamics and tissue regeneration, Talpha1 cannot replace TB-500. The decision follows the mechanism, not any general superiority.
The two peptides have orthogonal mechanisms (immune receptor agonism via TLR2/TLR9 vs. G-actin sequestration) and non-overlapping research endpoints. A winner exists only within a specific context: Thymosin Alpha-1 for immunology research, clinical data maturity, and anti-doping compliance; TB-500 for tissue repair and angiogenesis models. Since the evidence bases are asymmetric and not directly comparable and no head-to-head studies exist, a context-dependent verdict (no single overall winner) is the only factually correct one.
No standardized human dose; clinically IV 42-1260 mg (Tbeta4); community regimens in the mg range, s.c. weekly, not validated
Subcutaneous (established route, high bioavailability, Tmax 1-2 h)
Clinical (Tbeta4): IV, topical (gel), ophthalmic (drops); research context: s.c.
Terminal plasma half-life approx. 2 hours; no accumulation, return to baseline within 24 h
Short, approx. 1-2 hours (low mg doses); increases dose-dependently; rapid distribution phase
Approved drug product (thymalfasin/Zadaxin) in several countries; over 2,000 treated patients documented
Tbeta4 up to Phase 3 (ophthalmology only); the fragment TB-500 itself has practically no dedicated human data
Very well tolerated; mostly mild reactions (injection site, polyarthralgia)
Well tolerated in studies; theoretical risk of promoting tumor growth or angiogenesis has not been adequately studied
Lyophilizate refrigerated 2-8 °C; use promptly after reconstitution
Lyophilizate -20 °C (long-term), 2-8 °C briefly; reconstituted 2-8 °C, approx. 2-4 weeks
28 amino acids, N-acetylated, approx. 3109 Da, highly acidic, heat-stable
Active region of Thymosin Beta-4 (43 aa, approx. 4.96 kDa); central actin-binding motif LKKTETQ
Approved as thymalfasin (immunomodulatory drug product); not generally prohibited by WADA
Prohibited by WADA since 2011 (Section S2: peptide hormones, growth factors), prohibited at all times
Evidence note: The actin-sequestering and angiogenic mechanisms are well documented in vitro and in animal models; the evidence for systemic tissue repair effects specifically of the TB-500 fragment remains predominantly preclinical.
Despite the shared name “Thymosin,” Talpha1 and Tbeta4 are unrelated peptide families with different sequences, sizes, and functions. Talpha1 targets immune receptors (TLR2/TLR9) and coordinates the adaptive immune response; Tbeta4/TB-500 targets the cytoskeleton (G-actin) and controls migration and repair. Their mechanistic axes do not overlap: a “better or worse” comparison therefore makes sense only within a specific research endpoint.
The evidence base is asymmetric and not directly comparable. As an approved drug product (thymalfasin), Thymosin Alpha-1 has a broad clinical and PK dossier with a well-characterized immune mechanism 24. Thymosin Beta-4 reached Phase 3 in the narrow ophthalmic indication, while dermal/cardiac programs remained in Phase 1-2 89. Crucially, the TB-500 fragment itself has practically no human data of its own; its reputation for tissue repair rests on full-length Tbeta4 studies plus preclinical rodent models 7. No direct head-to-head studies exist.
This comparison is intended solely for scientific information and does not constitute medical advice, diagnosis, or treatment recommendation. None of the peptides described is approved as a drug for the research purposes named or for the use presented here. All dosage, activity, and safety information comes from the scientific literature and relates to laboratory research. TB-500/Thymosin Beta-4 has been prohibited by WADA since 2011. For research use only. Not for human consumption.
Both peptides are lyophilized, short-lived molecules (half-life approx. 1-2 h) with similar handling requirements, but they differ in long-term storage (Talpha1: 2-8 °C; TB-500: -20 °C). For purely methodological stability or reconstitution comparisons, both are suitable; the choice depends on the study design, not on the mechanism.
No, both are short-lived. Thymosin Alpha-1 has a terminal plasma half-life of about 2 hours without accumulation 2. For Thymosin Beta-4, the plasma half-life at low mg doses is likewise reported to be on the order of 1-2 hours, increasing dose-dependently. Neither of the two forms a long-term depot.
No. Their mechanistic axes are orthogonal: Thymosin Alpha-1 addresses immune receptors (TLR/IDO), TB-500 the cytoskeleton (G-actin). An immunological research endpoint cannot be covered by an actin-binding peptide, and vice versa. The choice must be aligned with the specific mechanism of the research question.
Both are handled as lyophilized powder. Thymosin Alpha-1 is stored refrigerated at 2-8 °C and used promptly after reconstitution. TB-500 is recommended for long-term storage at -20 °C (briefly 2-8 °C); once reconstituted, it is kept at 2-8 °C and used within about 2-4 weeks, while repeated freeze-thaw cycles should be avoided.
For the most part, no. The actin-sequestering and angiogenic mechanisms are well documented in vitro and in animal models 67. However, the usual positioning of the TB-500 fragment in sports and regeneration contexts rests predominantly on preclinical rodent models or anecdotal reports, not on controlled human studies with the fragment itself.
No standardized human dose; clinically IV 42-1260 mg (Tbeta4); community regimens in the mg range, s.c. weekly, not validated
Subcutaneous (established route, high bioavailability, Tmax 1-2 h)
Clinical (Tbeta4): IV, topical (gel), ophthalmic (drops); research context: s.c.
Terminal plasma half-life approx. 2 hours; no accumulation, return to baseline within 24 h
Short, approx. 1-2 hours (low mg doses); increases dose-dependently; rapid distribution phase
Approved drug product (thymalfasin/Zadaxin) in several countries; over 2,000 treated patients documented
Tbeta4 up to Phase 3 (ophthalmology only); the fragment TB-500 itself has practically no dedicated human data
Very well tolerated; mostly mild reactions (injection site, polyarthralgia)
Well tolerated in studies; theoretical risk of promoting tumor growth or angiogenesis has not been adequately studied
Lyophilizate refrigerated 2-8 °C; use promptly after reconstitution
Lyophilizate -20 °C (long-term), 2-8 °C briefly; reconstituted 2-8 °C, approx. 2-4 weeks
28 amino acids, N-acetylated, approx. 3109 Da, highly acidic, heat-stable
Active region of Thymosin Beta-4 (43 aa, approx. 4.96 kDa); central actin-binding motif LKKTETQ
Approved as thymalfasin (immunomodulatory drug product); not generally prohibited by WADA
Prohibited by WADA since 2011 (Section S2: peptide hormones, growth factors), prohibited at all times
Evidence note: The actin-sequestering and angiogenic mechanisms are well documented in vitro and in animal models; the evidence for systemic tissue repair effects specifically of the TB-500 fragment remains predominantly preclinical.
Despite the shared name “Thymosin,” Talpha1 and Tbeta4 are unrelated peptide families with different sequences, sizes, and functions. Talpha1 targets immune receptors (TLR2/TLR9) and coordinates the adaptive immune response; Tbeta4/TB-500 targets the cytoskeleton (G-actin) and controls migration and repair. Their mechanistic axes do not overlap: a “better or worse” comparison therefore makes sense only within a specific research endpoint.
The evidence base is asymmetric and not directly comparable. As an approved drug product (thymalfasin), Thymosin Alpha-1 has a broad clinical and PK dossier with a well-characterized immune mechanism 24. Thymosin Beta-4 reached Phase 3 in the narrow ophthalmic indication, while dermal/cardiac programs remained in Phase 1-2 89. Crucially, the TB-500 fragment itself has practically no human data of its own; its reputation for tissue repair rests on full-length Tbeta4 studies plus preclinical rodent models 7. No direct head-to-head studies exist.
This comparison is intended solely for scientific information and does not constitute medical advice, diagnosis, or treatment recommendation. None of the peptides described is approved as a drug for the research purposes named or for the use presented here. All dosage, activity, and safety information comes from the scientific literature and relates to laboratory research. TB-500/Thymosin Beta-4 has been prohibited by WADA since 2011. For research use only. Not for human consumption.
Both peptides are lyophilized, short-lived molecules (half-life approx. 1-2 h) with similar handling requirements, but they differ in long-term storage (Talpha1: 2-8 °C; TB-500: -20 °C). For purely methodological stability or reconstitution comparisons, both are suitable; the choice depends on the study design, not on the mechanism.
No, both are short-lived. Thymosin Alpha-1 has a terminal plasma half-life of about 2 hours without accumulation 2. For Thymosin Beta-4, the plasma half-life at low mg doses is likewise reported to be on the order of 1-2 hours, increasing dose-dependently. Neither of the two forms a long-term depot.
No. Their mechanistic axes are orthogonal: Thymosin Alpha-1 addresses immune receptors (TLR/IDO), TB-500 the cytoskeleton (G-actin). An immunological research endpoint cannot be covered by an actin-binding peptide, and vice versa. The choice must be aligned with the specific mechanism of the research question.
Both are handled as lyophilized powder. Thymosin Alpha-1 is stored refrigerated at 2-8 °C and used promptly after reconstitution. TB-500 is recommended for long-term storage at -20 °C (briefly 2-8 °C); once reconstituted, it is kept at 2-8 °C and used within about 2-4 weeks, while repeated freeze-thaw cycles should be avoided.
For the most part, no. The actin-sequestering and angiogenic mechanisms are well documented in vitro and in animal models 67. However, the usual positioning of the TB-500 fragment in sports and regeneration contexts rests predominantly on preclinical rodent models or anecdotal reports, not on controlled human studies with the fragment itself.
